JDRF and its JDRF Israel affiliate have established a research partnership with the Israel Science Foundation (ISF), a prominent research organization in Israel, to encourage innovative research focused on accelerating progress toward a cure for type 1 diabetes.
JDRF and ISF are committing up to $3 million each over a three-year period to support type 1 diabetes research in Israel.
“This partnership is an exciting opportunity to support innovative research to overcome some of the main hurdles we face in type 1 diabetes research today,” said Dr. Richard Insel, JDRF’s Chief Scientific Officer.
The partnership builds on JDRF’s long-time support of type 1 diabetes research in Israel. “With this program, we look to extend and build on these efforts and recruit more scientific talent from Israel to the field, and help accelerate progress toward our goal of a cure for type 1 diabetes and its complications,” Dr. Insel said.
The program will focus on developing a better understanding of the autoimmune response that causes type 1 diabetes and discovering novel therapeutic approaches to eliminating or preventing the autoimmune response. It will also look at developing beta cell therapies, which are treatments that restore the body’s ability to produce insulin by either replacing or regenerating the insulin-producing cells destroyed by type 1 diabetes. Research funded will address the challenges of developing replenishable sources of islet cells for transplantation and discovering new targets and pathways to regenerate endogenous beta cells in the body.
“JDRF Israel is proud to have initiated and managed this partnership with ISF, which will continue to put Israeli scientists at the forefront of diabetes research and to make contributions that will help bring about an end to type 1 diabetes,” said Ishay Eilat, Chairperson of JDRF Israel.